Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New site added to international phase II study of Litx

Dec. 9, 2003

Treatment commences in pivotal European phase II trial of clofarabine for ALL

Dec. 9, 2003

Allos completes RSR-13 NDA filing

Dec. 9, 2003

CC-5079 induces NF-B-independent apoptosis of hematopoietic cancer cells

Dec. 9, 2003

Potent in vitro effects of OSW-1 against human leukemia cells

Dec. 9, 2003

Enhanced apoptosis with LAQ-824 and Apo2L/TRAIL cotreatment

Dec. 9, 2003

CGP-76030 inhibits proliferation of imatinib-resistant, Bcr/Abl-transformed murine bone marrow cells

Dec. 9, 2003

Phase I study evaluates oral clofarabine in solid tumors

Dec. 5, 2003

Protein farnesyltransferase inhibitor R-115777 assessed in breast cancer model

Dec. 5, 2003

Preliminary phase II results reported for vinflunine in metastatic breast cancer

Dec. 5, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.